Rivaroxaban

Nkọwa dị mkpirikpi:

Aha API Ngosipụta Nkọwapụta US DMF EU DMF CEP
Rivaroxaban Ọgwụ mgbochi N'ime ụlọ TDP    


Nkọwa ngwaahịa

Mkpado ngwaahịa

Nkọwa ngwaahịa

ndabere

Rivaroxaban, 5-chloro-N-[[(5S) -2-oxo-3-[4- (3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl]methyl] thiophene-2 -carboxamide, bụ ihe na-eme ka obere molecule na-egbochi ihe Xa nke bụ ihe na-akpata coagulation n'oge dị oké egwu n'okporo ụzọ coagulation ọbara na-akpata ọgbọ nke thrombin na nhazi nke clot.Rivaroxaban na-ejikọta na Tyr288 na S1 akpa ego nke Xa site na mmekọrịta nke Tyr288 na chlorine n'ime chlorothiophene moiety.Mgbochi a na-agbanwe agbanwe (koff = 5x10-3s-1), ngwa ngwa (kon = 1.7x107 mol / L-1 s-1), na n'ụzọ dabere na ntinye uche (Ki = 0.4 nmol / L).A na-amụ Rivaroxaban ugbu a maka ọgwụgwọ VTE, mgbochi nke ọrịa obi na ndị ọrịa nwere nnukwu ọrịa obi, mgbochi nke ọrịa strok na ndị ọrịa nwere fibrillation atrial.

Ntụaka

Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza, Wolfgang Mueck, na Volker Laux.Rivaroxaban: ihe mgbochi ọnụ ọhụrụ Xa.Arterioscler Thromb Vasc Biol 2010;30 (3): 376-381

Nkọwa

Rivaroxaban (BAY 59-7939) bụ ike dị ukwuu,onye na-emechi ihe na-eme ihe na-ahụ maka Xa (FXa), na-enweta uru siri ike na ike mgbochi FXa (IC50 0.7 nM; Ki 0.4 nM).

 

Na Vitro

Rivaroxaban (BAY 59-7939) bụ onye na-emechi ọnụ, kpọmkwem Factor Xa (FXa) inhibitor na mmepe maka mgbochi na ọgwụgwọ nke arterial na venous thrombosis.Rivaroxaban asọmpi na-egbochi mmadụ FXa (Ki 0.4 nM) na> 10 000-fold nhọrọ ukwuu karịa maka proteases serine ndị ọzọ;ọ na-egbochikwa ọrụ prothrombinase (IC50 2.1 nM).Rivaroxaban na-egbochi FXa endogenous nke ọma na plasma mmadụ na oke bekee (IC50 21 nM) karịa plasma oke (IC50 290 nM).Ọ na-egosiputa mmetụta anticoagulant na plasma mmadụ, na-abawanye oge prothrombin ugboro abụọ (PT) ma na-arụ ọrụ thromboplastin akụkụ na 0.23 na 0.69.μM, n'otu n'otu.

 

Rivaroxaban (BAY 59-7939) bụ onye nwere ike na nhọrọ, onye na-egbochi FXa kpọmkwem nwere ọmarịcha ọrụ vivo yana ezigbo bioavailability ọnụ.Rivaroxaban (BAY 59-7939), nke iv bolus na-elekọta tupu mmalite thrombus, na-ebelata nhazi thrombus (ED50 0.1 mg/kg), na-egbochi FXa, ma na-agbatị dose PT dabere.PT na FXa na-emetụta ntakịrị na ED50 (mmụba okpukpu 1.8 na mgbochi 32%, n'otu n'otu).Na 0.3 mg / kg (ọgwụ nke na-eduga na njedebe zuru oke nke mmepụta thrombus), Rivaroxaban na-agbatị PT (3.2) ogologo oge.±0.5-fold) ma gbochie ọrụ FXa (65±3%).

 

Nchekwa

Ntụ ntụ

-20°C

Afọ 3
 

4°C

afọ 2
Na ihe mgbaze

-80 Celsius

Ọnwa isii
 

-20°C

1 ọnwa

Ọdịdị chemical

Rivaroxaban

Asambodo

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

njikwa mma

Quality management1

Atụmatụ18Ọrụ nlebanya na-agbanwe agbanwe nke akwadoro4, na6A na-akwado ọrụ ngo.

Quality management2

Usoro njikwa ogo mba ụwa dị elu etinyela ntọala siri ike maka ire ahịa.

Quality management3

Nlekọta dị mma na-aga n'ihu na usoro ndụ nke ngwaahịa ahụ niile iji hụ na ịdịmma na mmetụta ọgwụgwọ.

Quality management4

Ndị otu Regulatory Affairs ndị ọkachamara na-akwado ịdịmma chọrọ n'oge ngwa na ndebanye aha.

njikwa mmepụta

cpf5
cpf6

Ahịrị nkwakọ ngwaahịa Korea Countec

cpf7
cpf8

Taiwan CVC ahịrị nkwakọ ngwaahịa

cpf9
cpf10

Line CAM Board Ịtali

cpf11

Igwe na-akpakọrịta Fette German

cpf12

Ihe nchọpụta mbadamba ihe ngosi nke Japan

cpf14-1

Ụlọ njikwa DCS

Onye mmekọ

Mmekọrịta mba ụwa
International cooperation
Imekọ ihe ọnụ n'ụlọ
Domestic cooperation

  • Nke gara aga:
  • Osote:

  • Dee ozi gị ebe a ziga anyị ya

    Ụdị ngwaahịa